 Inactivation, Metabolic
"Inactivation, Metabolic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Reduction of pharmacologic activity or toxicity of a drug or other foreign substance by a living system, usually by enzymatic action. It includes those metabolic transformations that make the substance more soluble for faster renal excretion.
| Descriptor ID |
D008658
|
| MeSH Number(s) |
G03.495.244.450 G03.787.225.450 G07.690.725.225.450
|
| Concept/Terms |
Metabolic Detoxication, Drug- Metabolic Detoxication, Drug
- Detoxication, Drug Metabolic
- Drug Metabolic Detoxication
- Metabolic Detoxification, Drug
- Detoxification, Drug Metabolic
- Drug Metabolic Detoxification
- Drug Detoxication, Metabolic
- Detoxication, Metabolic Drug
- Metabolic Drug Detoxication
- Detoxication, Drug, Metabolic
- Detoxification, Drug, Metabolic
|
Below are MeSH descriptors whose meaning is more general than "Inactivation, Metabolic".
Below are MeSH descriptors whose meaning is more specific than "Inactivation, Metabolic".
This graph shows the total number of publications written about "Inactivation, Metabolic" by people in this website by year, and whether "Inactivation, Metabolic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 1 | 1 | | 2005 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 | | 2013 | 1 | 1 | 2 | | 2014 | 0 | 1 | 1 | | 2016 | 1 | 0 | 1 | | 2018 | 0 | 1 | 1 | | 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Inactivation, Metabolic" by people in Profiles.
-
Gaedigk A, Casey ST, Whirl-Carrillo M, Miller NA, Klein TE. Pharmacogene Variation Consortium: A Global Resource and Repository for Pharmacogene Variation. Clin Pharmacol Ther. 2021 09; 110(3):542-545.
-
Bhatt DK, Basit A, Zhang H, Gaedigk A, Lee SB, Claw KG, Mehrotra A, Chaudhry AS, Pearce RE, Gaedigk R, Broeckel U, Thornton TA, Nickerson DA, Schuetz EG, Amory JK, Leeder JS, Prasad B. Hepatic Abundance and Activity of Androgen- and Drug-Metabolizing Enzyme UGT2B17 Are Associated with Genotype, Age, and Sex. Drug Metab Dispos. 2018 06; 46(6):888-896.
-
Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Leeder JS. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med. 2017 01; 19(1):69-76.
-
de Wildt SN, Tibboel D, Leeder JS. Drug metabolism for the paediatrician. Arch Dis Child. 2014 Dec; 99(12):1137-42.
-
Zhong XB, Leeder JS. Epigenetic regulation of ADME-related genes: focus on drug metabolism and transport. Drug Metab Dispos. 2013 Oct; 41(10):1721-4.
-
Xie Z, Baba SP, Sweeney BR, Barski OA. Detoxification of aldehydes by histidine-containing dipeptides: from chemistry to clinical implications. Chem Biol Interact. 2013 Feb 25; 202(1-3):288-97.
-
Fu ZD, Csanaky IL, Klaassen CD. Effects of aging on mRNA profiles for drug-metabolizing enzymes and transporters in livers of male and female mice. Drug Metab Dispos. 2012 Jun; 40(6):1216-25.
-
Leeder JS. Developmental pharmacogenetics: a general paradigm for application to neonatal pharmacology and toxicology. Clin Pharmacol Ther. 2009 Dec; 86(6):678-82.
-
Gaedigk A, Ndjountch? L, Leeder JS, Bradford LD. Limited association of the 2988g > a single nucleotide polymorphism with CYP2D641 in black subjects. Clin Pharmacol Ther. 2005 Mar; 77(3):228-30; author reply 230-1.
-
de Wildt SN, Kearns GL, Hop WC, Murry DJ, Abdel-Rahman SM, van den Anker JN. Pharmacokinetics and metabolism of oral midazolam in preterm infants. Br J Clin Pharmacol. 2002 Apr; 53(4):390-2.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|